Staging classification of lung cancer: A critical evaluation

Clinics in Chest Medicine

Volumn 23, Issue 1, 2002, Pages 103-121

  Mountain, Clifton F ^a  

^a NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACCURACY; CANCER CLASSIFICATION; CANCER STAGING; CLINICAL PRACTICE; HUMAN; LUNG TUMOR; PRIORITY JOURNAL; PROGNOSIS; REVIEW; VALIDATION PROCESS;

EID: 0036189825     PISSN: 02725231     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0272-5231(03)00063-7     Document Type: Review

References (64)

1. Lung
2. Lung
3. Clinical staging of primary lung cancer
4. Pretreatment evaluation of non-small cell lung cancer
5. Tumor necrosis factor-α and transforming growth factor-β are significantly associated with better prognosis in non-small cell lung carcinoma: Putative relation with BCL-2-mediated neovascularization
6. Prognostic value of stage grouping and TNM descriptors in lung cancer
7. Nodal stage after induction therapy for stage IIIA lung cancer determines patient survival
8. PET in lung cancer
9. Angiogenesis and non-small cell lung cancer
10. CT demonstration of the 1996 AJCC-UICC regional lymph node classification for lung cancer staging
11. Surgery for non-small cell lung cancer with unsuspected metastasis to ipsilateral mediastinal or subcarinal lymph nodes (N2 disease)
12. Enquete permanent dans les centres anticancereux
13. Useful prognostic panel markers to express the biological tumor status in resected lung adenocarcinomas
14. Carcinoma of the lung: Evaluation of satellite nodules as a factor influencing prognosis after resection
15. Stage I non-small cell lung carcinoma: Analysis of survival and implications for screening
16. Non-small cell lung cancer: FDG-PET imaging
17. Nuclear medicine imaging of lung cancer
18. Deregulated expression of c-mos in non-small cell lung carcinoma: Relationship with p53 status, genomic instability, and tumor kinetics
19. Overexpression of dihydroldiol dehydrogenase as a prognostic marker of non-small cell lung cancer
20. Diagnosis and staging of lung cancer
21. Surgical results for small cell lung cancer based on the new TNM staging system
22. Lung and pleural tumors
23. Lung tumors (ICDO-162)
24. Lung tumors (ICDO-162)
25. Prognostic factors in patients with surgically resected stages I and II non-small cell lung cancer
26. Management of ipsilateral intrapulmonary metastases in the new TNM system for non-small cell lung cancer
27. Mediastinal lymph node evaluation by computed tomographic scan in lung cancer
28. A randomized trial of postoperative adjuvant therapy inpatients with completely resected stage II or IIIA non-small cell lung cancer
29. Effect of HER/neu expression on survival in non-small cell lung cancer
30. Surgery in limited stage small cell lung cancer
31. Staging techniques for lung cancer
32. The 1997 international staging system for non-small cell lung cancer: Have all the issues been addressed?
33. The role of positron emission tomography in evaluating mediastinal lymph node metastases in non-small cell lung cancer
34. Lung cancer and positron emission tomography with fluorodeoxyglucose
35. Staging non-small cell lung cancer with whole body PET
36. A new international staging system for lung cancer
37. Revisions in the international system for staging lung cancer
38. Surgical treatment of lung cancer
39. Regional lymph node classification for lung cancer staging
40. Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer
41. Lymph node mapping and curability of various levels of metastasis in resected lung cancer
42. Vascular endothelial growth factor, platelet-derived endothelial growth factor, and angiogenesis in non-small cell lung cancer
43. Prognostic evaluation of intrapulmonary metastasis in lung cancer
44. Management of stage III disease: Mediastinal adenopathy: The N2 lesion
45. Preoperative staging of non-small cell carcinoma with positron emission tomography
46. Neopterin: A prognostic variable in operations for lung cancer
47. Factors associated with false-positive staging of lung cancer by positron emission tomography
48. Gene replacement strategies for treatment of non-small cell lung cancer
49. Factors determining outcome after surgical resection of T3 and T4 lung cancers of the superior sulcus
50. Evaluation of new TNM lung cancer classification
51. Evaluation of fluorine-18 fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer
52. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimates of prognosis in potentially curative resected non-small cell lung cancer
53. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer
54. The prognosis of surgically resected N2 non-small cell lung cancer: The importance of clinical N status
55. Prognostic significance of polysialic acid expression in resected non-small cell lung cancer
56. MR imaging of pulmonary and mediastinal malignancies
57. Expression of nucleolar protein p120 in human lung cancer: Difference in histological types as a marker for proliferation
58. Survival in synchronous versus single lung cancer: Upstaging better reflects prognosis
59. Proceedings of a National Cancer Institute workshop: PET in oncology: A clinical research agenda
60. Detection of extrathoracic metastases by positron emission tomography in lung cancer
61. Postoperative prognosis in patients with non-small cell lung cancer with synchronous ipsilateral intrapulmonary metastasis